Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial.
about
Peripheral arterial disease assessment: wall, perfusion, and spectroscopyCalf muscle perfusion at peak exercise in peripheral arterial disease: measurement by first-pass contrast-enhanced magnetic resonance imaging.Systems biology of vascular endothelial growth factorsDose-dependent neovascularization-promoting effect of adenovirus vector CI-1023 in a rat hindlimb ischaemic model.Gene therapy in the treatment of peripheral arterial disease.Pharmacological revascularisation in coronary and peripheral vascular disease.Angiogenic and antiangiogenic gene therapy.Regeneration of vascularized bone.Increased antiangiogenic protein expression in the skeletal muscle of diabetic swine and patients.Therapeutic angiogenesis in critical limb ischemia.A phase I study of human cord blood-derived mesenchymal stem cell therapy in patients with peripheral arterial occlusive disease.Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8.Cellular endocytosis and gene deliveryTrimodal rescue of hind limb ischemia with growth factors, cells, and nanocarriers: fundamentals to clinical trials.Vascular endothelial growth factor stimulates differential signaling pathways in in vivo microcirculation.Angiogenic gene therapy does not cause retinal pathology.Magnetic nanoparticles enhance adenovirus transduction in vitro and in vivo.Quantitative microcomputed tomography analysis of collateral vessel development after ischemic injury.Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage.
P2860
Q30434383-173488B0-74D5-4A4A-9746-1ADC902490C7Q30434965-408D8EC2-F023-4EF1-ADE8-21E88718E41DQ30438979-500639C8-83F0-4F1D-B5EE-81DB1DF71648Q31114069-ED73E0C7-98FA-472E-A579-21565DD54275Q34070287-E99DB043-21DE-4ADF-B5F1-1F585EB85D88Q35906980-659E90E5-118D-476A-9778-1A39BF033124Q36288905-CD7F5BF5-FDBE-451F-8969-E8DE5349B382Q36474280-FC292B75-816E-4F6E-B3D4-B2F370BE0901Q37045424-87C4340B-F13B-4076-A5FB-97E08E9FB160Q37142832-1B0735AF-A7D8-4A73-B1F5-56D11A6A73D8Q37344037-D25E667D-5EB5-4E60-9E7A-7F72D114767EQ37599900-FF782E72-8FDA-4716-9E25-E72A1619CD36Q37747047-DAF8C141-9118-4496-BA4B-14FD0D5302DDQ39240834-0D207888-16DA-4DD7-99AD-41A171976497Q39685561-B71A22DD-706E-4CD3-8BEE-871B192D107DQ45869416-0B4D09C8-DFA4-4325-ABEA-AA9C8DAAE803Q45875626-983A472D-6033-4D28-87F6-8A82DE6A1B89Q47963643-881BE2AD-1D98-496E-B4BB-6745CA6B76ADQ48358527-52EF1074-7849-42E4-82F5-BC651442221F
P2860
Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Adenoviral-mediated gene trans ...... results from a phase I trial.
@en
Adenoviral-mediated gene trans ...... results from a phase I trial.
@nl
type
label
Adenoviral-mediated gene trans ...... results from a phase I trial.
@en
Adenoviral-mediated gene trans ...... results from a phase I trial.
@nl
prefLabel
Adenoviral-mediated gene trans ...... results from a phase I trial.
@en
Adenoviral-mediated gene trans ...... results from a phase I trial.
@nl
P2093
P2860
P921
P1433
P1476
Adenoviral-mediated gene trans ...... results from a phase I trial.
@en
P2093
Emile R Mohler
Henrik Rasmussen
Jeffrey D Trachtenberg
Jeffrey W Olin
Raphael Pak
Ronald G Crystal
Sanjay Rajagopalan
P2860
P356
10.1191/1358863X03VM460OA
P577
2003-01-01T00:00:00Z